NCT01447901View on ClinicalTrials.gov

Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in Other Studies

TerminatedOBSERVATIONAL
Enrollment

19

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Hyperlipoproteinemia Type I
Trial Locations (1)

G7H 7P2

ECOGENE-21 Clinical Trial Center, Chicoutimi

Sponsors

Collaborators (1)

ICON plc
All Listed Sponsors
collaborator

ICON plc

INDUSTRY

lead

Amsterdam Molecular Therapeutics

INDUSTRY